News
RSNA: Neurologic Complications of COVID-19 Examined
In patients with critical findings identified on neuroimaging, most common comorbidities were hypertension, diabetes
Your search for diabetes returned 2209 results
Drugs in the Pipeline
Interim Data Show COVID-19 Vaccine Candidate mRNA-1273 Near 95% Effective
The placebo-controlled COVE study is investigating the efficacy and safety of mRNA-1273 at the 100mcg dose (given intramuscularly in a 2-dose series, approximately 28 days apart) in more than 30,000 adults aged 18 years and older.
Features
A Review of Treatments for HFrEF and Expert Q&A
Despite substantial advances in therapeutic options for HFrEF, significant gaps remain in the use of guideline-directed medical therapy in these patients.
CHEST 2020 COPD In-depth
Acute COPD Exacerbations May Be Linked to Higher HbA1c Levels
Patients with chronic obstructive pulmonary disease (COPD) who have higher levels of HbA1c are at increased risk for hospital admission for acute exacerbations.
CHEST 2020
COVID-19 With COPD: Fewer Hospitalizations, But Greater Mortality
Chronic obstructive pulmonary disease may be associated with higher rates of mortality in patients with coronavirus disease 2019.
CHEST 2020
Diabetes Increases Risk of In-Hospital Mortality in Patients With COVID-19
Hospitalized patients with severe COVID-19 and diabetes are less likely to be discharged from the hospital and are more likely to experience in-hospital mortality compared with patients without diabetes.
CHEST 2020
Effect of Positive Airway Pressure Therapy on Cardiovascular Risk in Sleep Apnea
Patients with sleep apnea who received positive airway pressure therapy did not exhibit reduced cardiovascular risk compared with patients who received usual care.
CHEST 2020
Tacrolimus vs Cyclosporine as Maintenance Therapy in Lung Transplant Recipients
Among lung transplant recipients, tacrolimus compared to cyclosporine may be associated with decreased incidence of bronchiolitis obliterans syndrome and number of acute rejection episodes.
News
Ertugliflozin Noninferior for CV Outcomes in T2DM With ASCVD
Ertugliflozin is noninferior to placebo for the primary end point of major adverse cardiovascular events.
News
Proton Pump Inhibitor Use Linked to Increased Diabetes Risk
Type 2 diabetes risk increased with increasing length of PPI use, particularly use for more than two years.
